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scriptional activity of these nuclear receptors is regulated by the nuclear receptor corepressors (NCORs),
including NCOR1. In this review we describe the function of NCOR1 as a central immunometabolic
regulator and focus on its role in atherosclerosis and associated immunometabolic diseases.
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Atherosclerotic cardiovascular disease is part of chronic immunometabolic disorders such
as type 2 diabetes and nonalcoholic fatty liver disease. Their common risk factors
comprise hypertension, insulin resistance, visceral obesity, and dyslipidemias, such as
hypercholesterolemia and hypertriglyceridemia, which are part of the metabolic
syndrome. Immunometabolic diseases include chronic pathologies that are affected by
both metabolic and inflammatory triggers and mediators. Important and challenging
questions in this context are to reveal how metabolic triggers and their downstream
signaling affect inflammatory processes and vice-versa. Along these lines, specific nuclear
receptors sense changes in lipid metabolism and in turn induce downstream inflammatory
and metabolic processes. The transcriptional activity of these nuclear receptors is
regulated by the nuclear receptor corepressors (NCORs), including NCOR1. In this
review we describe the function of NCOR1 as a central immunometabolic regulator and
focus on its role in atherosclerosis and associated immunometabolic diseases.
Keywords: atherosclerosis, cardiometabolic, corepressor complex, NCoR1, nuclear receptor signaling,
immunometabolism, mechanisms of disease, transcriptional regulation
INTRODUCTION
Atherosclerosis is characterized by the accumulation of immune cells, cholesterol species and other
lipids in the intimal space of arteries. The disease primarily affects large, elastic, and high-pressure
vessels, such as the coronary, renal, femoral, and carotid arteries. The complex pathophysiology is
triggered by genetic and environmental risk factors, including lipid species and metabolites (e.g.,
cholesterol, specific fatty acids, carnitine), as well as by hypertension, diabetes and obesity (1–3).
Molecular, genetic, dietary and pharmacological studies over the last decades suggest that
hyperlipidemia, especially hypercholesterolemia, combined with the genetic predisposition is a
major trigger of atherogenesis (4–9). Nevertheless, recent research showed that other metabolic and
inflammatory processes are closely interconnected at the cellular level as well as via intra- and inter-
organ communication (10–12) (Figure 1).
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IMMUNOMETABOLIC INTEGRATORS
The signaling cascades that are activated by inflammatory and
metabolic triggers and/or mediators converge at key transcriptional
regulators, which in turn coordinate the expression of specific
target genes and atherogenic processes. Whether individual target
genes are activated or repressed depends on several other factors,
such as folding and compaction of the chromatin, posttranslational
modifications of histones by chromatin-modifying enzymes,
functional alterations by noncoding RNAs, and recruitment of
the transcriptional machinery, including transcription factors and
importantly also transcription cofactors, i.e. transcriptional
corepressors and coactivators (13–16).
Lipid-Responsive Nuclear Receptors
With Immunometabolic Functions
Nuclear receptors are a large family of druggable transcription
factors that exert important functions in development, metabolism,
and immune response (17, 18). Consequently, several nuclear
receptors do affect the development of atherosclerosis and
associated cardiometabolic diseases (reviewed in (19)). While the
role of lipid-binding nuclear receptor in metabolism is well
established, studies over the last decade demonstrated that several
of these nuclear receptors, including PPARg, LXRs, and LRH-1,
mediate transrepression of pro-inflammatory molecules in the liver
and/or immune cells, such as macrophages and T cells (20–25).
Therefore, these nuclear receptors act as direct immunometabolic
regulators and play an important role in atherogenesis.
NCOR1—An Emerging Regulator
of Immunometabolic Processes
Given their central role to integrate upstream information and
regulate the expression of downstream target genes, specific
transcriptional cofactors function as central immunometabolic
regulators. About 300 transcription cofactors are known to exist
in mice and human cells (26). However, only a fraction of those is
expressed in a specific cell type or tissue, and their function is
restricted to certain pathways and transcription factors (14, 15).
Some of these factors are involved in inflammatory mechanisms,
others known to exert metabolic functions.
Could research on (anti-)atherogenic corepressor complexes
provide answers to the key question of causality between
metabolic and inflammatory changes? One large nuclear
receptor corepressor complex that has been studied extensively
in vitro and in vivo in the last years is nuclear receptor
corepressor 1 (NCOR1) (Figure 2).
NCOR1 serves as scaffolding protein that forms the basis for a
large corepressor complex, including protein deacetylases [including
class I (HDAC3), class II (HDAC4, 5, 7, and 9) and class III (SIRT1)
KDACs], transducin beta-like 1 (TBL1) and TBLR1, two highly
related F box/WD40-containing factors, and the G-protein-pathway
suppressor 2 (GPS2) (27, 28). The molecular functions and (patho-)
physiological role of HDAC3, class II HDACs, GPS2, and TBL1 has
been extensively reviewed (29–31). Although germline Ncor1-/- and
Ncor2-/- mice are embryonically lethal (32, 33), they enabled to
establish important roles for NCOR1 in erythropoiesis, T-cell, and
central nervous system development, whereas NCOR2 contributes
to the morphological development of the heart (32–34). Targeted
deletions of NCOR1 in immune cells, liver, adipose tissue, and
muscle demonstrated that it affects pro- and anti-inflammatory
gene signatures, mitochondrial function, lipid metabolism, insulin
sensitivity, intestinal cholesterol absorption, thereby highlighting
its immunometabolic functions, which will be discussed below (21,
35–41). To the best of our knowledge there are no studies
addressing the tissue-specific deletion of Ncor2, which is
essential to study the cell-specific function of a gene, especially
for genes that are expressed in nearly all cells and organs and thus
regulate multiple processes (e.g., a detailed expression pattern of
Ncor1 and Ncor2 in mice can be found at Tabula muris (https://
tabula-muris.ds.czbiohub.org). Therefore, this review will focus on
tissue-specific functions of NCOR1.
NCOR1 Complex in Macrophages
Monocyte-derived macrophages are the most abundant immune
cell population found in atherosclerotic lesions and plaques.
They take up oxidized LDL (oxLDL) in an uncontrolled
fashion, secrete pro-inflammatory cytokines that recruit T cells,
and fall apart in a necrotic fashion, thus promoting plaque
growth and destabilization (42, 43). Silencing of macrophage
NCOR1 in vitro produces the same phenotype of activated
FIGURE 1 | Immunometabolic dysregulation promotes atherogenesis. Contribution of different organs and immunometabolic mediators to the chronic dysregulation
that promote atherogenesis.
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macrophages: increased expression pro-inflammatory cytokines,
chemokines and metalloproteases, and enhanced macrophage
invasiveness (21). Mechanistically, it was proposed that the
NCOR1 corepressor complex acts as a transcriptional checkpoint
for these inflammatory genes: In the absence of a nuclear receptor
ligand, NCOR1 is recruited to target genes and interacts with
unphosphorylated c-Jun bound to target promoters, thus
repressing pro-inflammatory gene expression. Upon stimulation
with an innate inflammatory stimulus, such as LPS, a structural
change in the ligand-binding domain of the nuclear receptor
reduces its affinity to NCOR1, hence simultaneously increasing
the affinity to coactivators (44). TBLR1 plays a crucial function as
an E3-ligase that directs the ligand-dependent ubiquitination and
proteasome-mediated clearance of NCOR1 and histone deacetylase
3 (HDAC3) from the promoter of target genes (45). Moreover, pro-
atherosclerotic minimally oxidized LDL (oxLDL) promotes JNK-
dependent derepression of AP-1 by releasing NCOR1 from the
promoter of chemokine genes (40). Taken together, these in vitro
studies suggest that absence of NCOR1 exacerbates the
inflammatory response in macrophages.
Paradoxically, the in vivomyeloid cell-specific deletion of Ncor1
repressed inflammatory gene expression and improved insulin
sensitivity in a diet-induced obesity mouse model (39). Li et al.
suggest that deletion of Ncor1 in adipose tissue macrophages leads
to a derepression of LXR target genes, increased expression of de
novo lipogenesis and fatty acid desaturation genes, and subsequent
production of anti-inflammatory w3 fatty acids, which in turn
suppress inflammatory activation of macrophages (39) (Figure 2).
Using a similar loss-of-function approach, Oppi et al. recently
showed that the myeloid cell-specific deletion of Ncor1 increased
atherosclerosis at the aortic sinus and the thoraco-abdominal
aorta in Ldlr knockout mice (41). At the molecular level NCOR1
was found to bind to the Cd36 promoter thus repressing PPARg-
driven Cd36 expression. Consequently, peritoneal macrophages
from Ncor1-deficient mice had increased CD36-mediated oxLDL
accumulation and foam cell formation (Figure 2). Interestingly,
Ncor1-deficient macrophages displayed an increased expression
of both anti- and pro-inflammatory genes. Moreover, analyses of
omics-datasets obtained from human plaque specimens
suggested that NCOR1-driven PPARg suppression is also
protective in human plaque development and vulnerability (41).
The data fromOppi et al. and Li et al. are partially controversial
(39, 41). Two major reasons could explain the differences. First, the
genetic background of the mice: Myeloid cell-specific Ncor1
knockout mice on a ‘wildtype’ versus Ldlr-/- background. The
Ldlr deficiency shifts the lipoprotein metabolism towards a
humanized profile with very high LDL-cholesterol levels, which
makes this mouse model prone to develop atherosclerosis and
display a pro-inflammatory signature (9, 46). Second, the use of the
experimental diets: High-fat diet to study the impact of NCOR1 on
diet-induced obesity versus high-cholesterol diet to assess
atherogenesis. It is known from numerous studies that diets
differently affect major immune and metabolic processes and
hence the development of chronic immunometabolic diseases,
especially when investigating lipid-sensitive nuclear receptor
signaling such as LRH-1 (47–51).
The phenotype of myeloid cell-specific Hdac3 knockout mice
is partially resembling the data from Oppi et al. (41, 52).
Hoeksema et al. showed that Hdac3-deficient mice develop
more atherosclerotic plaques in the aortic sinus compared to
control mice (52). Furthermore, Hdac3-deficient macrophages
displayed an anti-inflammatory wound-healing like phenotype.
FIGURE 2 | Regulation of immunometabolic processes by the NCOR1 complex. Scheme illustrating how transcriptional corepressor complexes repress the function
of nuclear receptors and thus regulate key inflammatory and metabolic processes in the liver and macrophages that are involved in the pathophysiology of
cardiometabolic diseases. CHOL, cholesterol; FA, fatty acid; oxLDL, oxidized LDL; PL, phospholipid.
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On the other side, atherosclerotic plaques from myeloid cell-
specific Hdac3 knockout mice displayed increased collagen
disposition and enlarged protective fibrous caps, while the
myeloid cell-specific Ncor1 knockout plaques had increased
necrotic cores (41).
In line with the data from Oppi et al. (41), Fan et al. showed
that myeloid cell-specific Gps2-knockout mice display an
increased expression of pro-inflammatory cytokines and
chemokines, such as Ccl2 and Ccl7, which is characteristic of
pro-inflammatory M1-type macrophage activation (53).
Moreover, the authors used palmitate as obesity-linked
metabolic trigger of inflammation and observed that Gps2-
deficient macrophages had an elevated pro-inflammatory gene
signature (53). Vice-versa, transplantation of Gps2-
overexpressing bone marrow into two mouse models of obesity
reduced inflammation and improved insulin sensitivity in
recipient mice (53). Moreover, docking of GPS2 and LXR
stimulate H3K9 demethylation on the Abcg1 promoter, thus
promoting its expression and mediating cholesterol efflux to
HDL particles in monocytic THP-1 cells (54). Contrary to the
induction of Abcg1 via LXR, GPS2 interacts with NF-kB to
promote the expression of Abca1 upon LPS stimulation (55).
These elegant studies demonstrate how GPS2 promotes
macrophage cholesterol efflux upon different stimuli, i.e. via
oxysterol-triggered LXR activation or via LPS-driven NF-kB
activation. Interestingly, the activation of both processes by
GPS2 is independent of NCOR1-HDAC3 recruitment (54, 55).
Aside from its effects on atherosclerotic plaques and
metabolism, macrophage NCOR1 seems to play a pivotal role
in the heart. Genetic deletion of Ncor1 in macrophages led to
reduced infarct size and improved cardiac function in mice with
experimental myocardial infarction (56). These findings were
explained by suppression of inflammatory transcriptional
programs (interleukin‐1b, interleukin‐6, AP-1 and nuclear
factor‐kB) and reduced macrophage proliferation (due to
inhibition of cell cycle progression). Hence, macrophage
NCOR1 may act as an upstream regulator of myocardial
inflammation thus participating to left ventricular hypertrophy,
diastolic dysfunction and microvascular disease, key hallmarks of
heart failure (57). In the same study, macrophage NCOR1
deficiency markedly inhibited neointimal hyperplasia and
vascular remodeling in a mouse model of arterial wire injury
(56). Taken together, these results suggest that selective
modulation of NCOR1 in macrophages could have important
implications for the prevention of myocardial ischemic damage,
heart failure, coronary heart disease and intracoronary stent
restenosis. Further molecular work and preclinical studies are
needed to better explore the potential of NCOR targeting
approaches in cardiovascular disease.
NCOR1 Complex in the Liver
The liver plays a crucial role in the development of
atherosclerosis by regulating metabolic and inflammatory
processes, such as the expression of pro-inflammatory
cytokines and acute phase response proteins, the secretion of
VLDL particles, the uptake of cholesterol from the circulation,
and the biliary cholesterol excretion. An immunometabolic
dysregulation in the liver can promote nonalcoholic fatty liver
disease and the development of atherosclerosis. Importantly,
nonalcoholic fatty liver disease leads to adverse cardiovascular
functions, such as increased oxidative stress and endothelial
dysfunction, hypercoagulability, and accelerated development
of atherosclerosis (58–60).
Several studies addressed the physiological functions of
NCOR1, NCOR2, and HDAC3 in the liver, which target
several lipid-responsive nuclear receptors (Figure 2) (24, 28,
29, 61–67). The role of NCOR1 in liver energy metabolism is
particularly interesting during the fasting-feeding transition:
both HDAC3 and NCOR1 are known to repress lipogenic
genes, but paradoxically, NCOR1 was also reported to be
critical for inhibition of PPARa, hepatic fatty oxidation and
ketogenesis (63, 64). This is due to the ability of NCOR1 to select
its repressor targets in a context-dependent manner to
orchestrate liver energy metabolism depending on the energy
status of the cell (37). Upon feeding, high levels of glucose and
insulin activate the target of rapamycin complex 1 (mTORC1)-
AKT signaling pathway, thus phosphorylating serine 1460 of
NCOR1 (pS1460 NCOR1) (Figure 2). pS1460 decreases the
ability of NCOR1 to interact with LXR, thus promoting the
transcription of lipogenic LXRs target genes, and conversely, by
fostering the interaction with PPARa and ERRa, with
subsequent repression of downstream ketogenic and Oxphos
genes (37).
Besides being regulated by phosphorylation in the liver, the
translation of NCOR1 can also be blocked by the microRNA
miR-199a-5p (68) (Figure 2). The authors used a bioinformatic
approach to identify miRNAs affected in a non-alcoholic
steatohepatitis (NASH) model induced by a methionine-
choline−deficient (MCD) diet. The MCD diet increased miR-
199a-5p expression, which in turn blocks the translation of the
Ncor1 mRNA by binding to a conserved 3’ untranslated
region (68).
To assess the function of NCOR1 in thyroid hormone
receptor (TR) regulation, the group of A. Hollenberg generated
a truncated form of NCOR1 which lacks the two main nuclear
receptor interacting domains (NCOR1DID) and thus, for
example, cannot interact with TRs or LXRs (69, 70).
Interestingly, they found that mice with a disrupted nuclear
receptor binding domain show a reduced content of cholesterol
in the liver and an increased synthesis of alternative bile acid. In
turn, these less hydrophobic bile acids have a lower capacity to
bind fats and sterols in the intestine and thus reduce their
absorption (38). The increased expression of alternative bile
acid synthesis genes is a consequence of TRb1 de-repression
caused by the mutant NCOR1 (38).
GPS2 exerts protective function in the liver by interacting with
SUMOylated nuclear receptors, such as LRH-1 and LXRb, to
repress inflammatory cytokine expression during the hepatic acute
phase response (71). On the other side, hepatic deletion of GPS2
reduces nonalcoholic steatohepatitis via induction of PPARa-
driven lipid catabolism (67). This repression of PPARa happens
in cooperation with NCOR1, but not NCOR2 (67). Conversely to
Geiger et al. NCOR1 in Cardiometabolic Disease
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the GPS2 knockouts, hepatic deletion of TBL1 promotes
hypertriglyceridemia and hepatic steatosis on both a normal
chow or high-fat diet by impairing PPARa-driven lipid
catabolism (72). The induction of PPARa was mediated by
increased recruitment of NCOR1-HDAC3 complexes in the
absence of TBL1 (72). These data underline that the repressive
function and target specificity of the NCOR1 complex is largely
dependent on its co-regulators.
NCOR1 in Cardiomyocytes
Previous studies demonstrated that NCOR1 deficiency increases
the activity of MEF2d in skeletal muscle (35). In a recent
publication, Li et al. affirmed the suppressive role of NCOR1 in
regulating the size of cardiomyocytes, presenting strong evidence
of interactions among NCOR1, MEF2, and class IIa HDACs,
being MEF2a and MEF2d key transcription factors interceded
the impact of NCOR1 on cardiomyocyte size (73). As Li et al.
described, NCOR1 may be considered as a stress-responsive and
cardioprotective regulator during cardiac hypertrophy, showing
that its deficiency led to cardiac hypertrophy under physiological
condition and aggravated hypertrophy induced by pressure
overload (73).
NCOR1 usually cooperates with HDACs to execute its
repressive activities (28). The regulatory paradigm in cardiac
hypertrophy involves alterations in gene expression that is
mediated by chromatin remodeling. HDACs remove the acetyl
group from histones, resulting in its hypoacetylation, which
diminishes chromatin accessibility for transcription factors,
leading to repression of transcription (74). The Class I HDAC3
enzyme participates in the repressive activities of NCOR1, and its
deficiency in cardiomyocytes causes severe cardiac hypertrophy
at an early stage. Interestingly, Li et al. identified class IIa to be
involved in the process of cardiomyocytes, demonstrating that
NCOR1 works more likely through class IIa instead of class I to
affect cardiac hypertrophy (73).
BCL6/NCOR1-Mediated Repression
of Inflammation
B cell lymphoma-6 (BCL6) belongs to a class of zinc-finger
transcription factors and acts as a transcriptional repressor. It
regulates the development of germinal centers, B and T cells,
coordinates the activation of macrophages, and was described as
a proto-oncogene (75). Importantly, the interaction of BCL6
with NCOR complexes is essential to mediate its transrepressive
activity in several biological processes (75, 76).
The PPARd agonist GW0742 protects against angiotensin II
(AngII)-accelerated atherosclerosis by inducing the expression of
the Bcl6, and the regulators of G protein-coupled signaling (RGS)
proteins RGS4 and RGS5, which in turn inhibit the expression of
pro-inflammatory and atherogenic genes (77). Interestingly,
ChIP-seq data demonstrate that the BCL6 and NCORs
cistrome overlap in about 50% of all DNA binding sites, and
that binding sites that are synergistically bound by BCL6 and
NCORs are highly enriched for inflammatory and atherogenic
NF-kB target genes (78).
The deletion of Bcl6 in the liver leads to a derepression of
PPARa-driven enzymes mediating fatty acid oxidation and thus
protects against high-fat diet-induced hepatic steatosis (79).
Interestingly, binding of the corepressors NCOR1, NCOR2 and
HDAC3 to BCL6-binding sites was reduced in Bcl6-deficient
livers, and these sites displayed increased enhancer/promoter
activity as shown by enhanced histone 3 lysine 27 acetylation
(H3K27ac) (79). These data suggest that hepatic BCL6 recruits a
subset of NCOR/HADC3 complexes to the promoter of specific
target genes regulating lipid metabolism.
Potential Functions of the NCOR1
Complex in Endothelial and T Cells
So far, the role of NCOR1 using an endothelial cell-specific
genetic model has not been explored. Therefore, this section is
limited to describe the function of its tight cofactor HDAC3 (28).
HDAC3 is essential for endothelial monolayer survival and
integrity. Studies demonstrated that HDAC3 is engaged in the
differentiation of embryonic stem cells into endothelial
progenitors and determinant for endothelial cell survival (64).
Zampetaki et al. demonstrated that disturbed flow induces
transient stabilization of the HDAC3 protein in endothelial
cells. It happens through the activation of the VEGFR2 and
PI3 kinase signaling pathways (80). HDAC3 expression increases
near branch openings compared with areas of high laminar flow,
which was also confirmed by exposure of endothelial cells to
disturbed flow in vitro (80). It is therefore likely that NCOR1
might be involved in these processes as well.
To obtain a good overview about the function of NCOR1 in T
cells we refer to an excellent review from Muller et al. (81). Most
studies assessed the role of NCOR1 during T cell development,
while only a few focused on its function in mature T cells in
pathophysiological conditions. The lethal phenotype of the
complete Ncor1 knockout mice developed by Jepsen et al.
demonstrated that constitutive Ncor1-deficiency conferred
impaired thymocyte development (33). Further studies using
T cell-specific deletions of Ncor1 in mice revealed that the
number of double negative thymocytes and peripheral T cells
are decreased in the absence of NCOR1 (82, 83). Recently, it was
shown that NCOR1 regulates the function of CD4+ and Th1
cells by regulating the expression of IFN-g (84). Consistently,
Zhang et al. showed that deletion of Ncor1 in male SJL T cells
disrupted the fenofibrate-driven repression of IFN-g synthesis,
possibly also explaining differences in Th1 responses between
male and female mice (85). Another interesting report
demonstrated that NCOR1 represses the tolerogenic program
in dendritic cells. As a consequence, dendritic cell-specific Ncor1
knockout mice display an increased number of FoxP3+
regulatory T cells (86). In terms of atherogenesis, this could
turn into a protective effect.
PERSPECTIVES
Research over the past decades identified various molecular factors
that affect atherogenesis, including inflammatory and metabolic
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regulators (2, 87, 88). In the last years, we have learned that
immunometabolic pathways are often interconnected, and we are
now starting to understand the major factors involved in
these immunometabolic mechanisms (10, 11). Targeting
immunometabolic pathways, e.g., those regulated by NCOR1,
might become an attractive approach to prevent the development
of atherosclerosis since they regulate various processes that promote
the development of the disease. Moreover, since these pathways are
also implicated in the development of other chronic
immunometabolic diseases, such as obesity, type 2 diabetes, and
nonalcoholic fatty liver disease, their mechanistic dissection will be
relevant to understand development and progression of
immunometabolic diseases on a broader scale.
Which could be suitable strategies to target NCOR1? One
option would be to develop small molecule agonists or
antagonists that interfere or facilitate the interaction of
NCOR1 to a specific target nuclear receptor. Although this
would be a specific approach, it would be very laborious and
time-consuming. Another option is offered by current
developments in gene therapy (including CRISPR therapeutics)
and small interference RNA (siRNA) medicine, which offer
excellent future targeting opportunities. The liver is an easily
accessible target organ and new emerging drugs using siRNAs
demonstrate that transcribed RNA can be targeted in a liver-
specific fashion by conjugating the synthetic siRNA to
triantennary N-acetylgalactosamine carbohydrates (e.g., as it is
used to target PCSK9 in the liver (89, 90)). However, specifically
targeting other organs or cells, such as cardiomyocytes and
macrophages, continues to be challenging. Moreover, the
identification of atherogenic targets, such as CD36 in
macrophages (41), might lead to the identification of druggable
targets and hence to the development of new therapeutic
strategies to treat atherosclerotic disease patients that are at a
very high risk to suffer a transient ischemic attack, stroke or acute
coronary syndrome.
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